1/15
06:42 am
bmy
JPM26: BioNTech gears up for multiproduct oncology status by 2030 [Yahoo! Finance]
Low
Report
JPM26: BioNTech gears up for multiproduct oncology status by 2030 [Yahoo! Finance]
1/15
06:42 am
bmy
Central Nervous System Therapeutic Market Report 2025-2033: Key Drivers, Regional Nuances, Competitive Dynamics | Astute Analytica [Yahoo! Finance]
Low
Report
Central Nervous System Therapeutic Market Report 2025-2033: Key Drivers, Regional Nuances, Competitive Dynamics | Astute Analytica [Yahoo! Finance]
1/14
01:01 pm
bmy
Bristol-Myers Squibb Reports Positive Phase 3 SCOUT-HCM Results for Camzyos in Adolescent Patients [Yahoo! Finance]
Low
Report
Bristol-Myers Squibb Reports Positive Phase 3 SCOUT-HCM Results for Camzyos in Adolescent Patients [Yahoo! Finance]
1/14
12:12 pm
bmy
Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference [CNBC]
Low
Report
Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference [CNBC]
1/14
03:42 am
bmy
[Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) [Yahoo! Finance]
Low
Report
[Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) [Yahoo! Finance]
1/13
08:47 pm
bmy
What You Need To Know Ahead of Bristol-Myers Squibb's Earnings Release [Yahoo! Finance]
Low
Report
What You Need To Know Ahead of Bristol-Myers Squibb's Earnings Release [Yahoo! Finance]
1/13
11:36 am
bmy
JPM26: J&J reveals oncology strategy [Yahoo! Finance]
Low
Report
JPM26: J&J reveals oncology strategy [Yahoo! Finance]
1/13
10:59 am
bmy
Bristol Myers Squibb (NYSE:BMY) had its price target raised by analysts at Leerink Partners from $54.00 to $60.00. They now have an "outperform" rating on the stock.
Low
Report
Bristol Myers Squibb (NYSE:BMY) had its price target raised by analysts at Leerink Partners from $54.00 to $60.00. They now have an "outperform" rating on the stock.
1/13
10:56 am
bmy
Radiopharmaceuticals Market to Worth Over US$ 13.4 Billion by 2033 | Astute Analytica [Yahoo! Finance]
Low
Report
Radiopharmaceuticals Market to Worth Over US$ 13.4 Billion by 2033 | Astute Analytica [Yahoo! Finance]
1/12
10:21 am
bmy
Scotiabank Raises Bristol-Myers (BMY) PT to $60 Citing Catalyst-Rich 2026 Growth [Yahoo! Finance]
Low
Report
Scotiabank Raises Bristol-Myers (BMY) PT to $60 Citing Catalyst-Rich 2026 Growth [Yahoo! Finance]
1/12
08:32 am
bmy
Par Health Names Dr. William Larkins as EVP and Chief Scientific Officer and President, Sterile Injectables [Yahoo! Finance]
Low
Report
Par Health Names Dr. William Larkins as EVP and Chief Scientific Officer and President, Sterile Injectables [Yahoo! Finance]
1/12
07:20 am
bmy
Precede Biosciences Secures $83.5M in Total Financing to Scale Next-Generation Precision Diagnostics Platform [Yahoo! Finance]
Low
Report
Precede Biosciences Secures $83.5M in Total Financing to Scale Next-Generation Precision Diagnostics Platform [Yahoo! Finance]
1/12
06:59 am
bmy
Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
Low
Report
Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
1/10
07:02 pm
bmy
Did UBS's Pipeline-Driven Upgrade Just Shift Bristol-Myers Squibb's (BMY) Investment Narrative? [Yahoo! Finance]
Low
Report
Did UBS's Pipeline-Driven Upgrade Just Shift Bristol-Myers Squibb's (BMY) Investment Narrative? [Yahoo! Finance]
1/9
09:47 pm
bmy
How Recent Developments Are Shaping The Bristol Myers Squibb (BMY) Investment Story [Yahoo! Finance]
Low
Report
How Recent Developments Are Shaping The Bristol Myers Squibb (BMY) Investment Story [Yahoo! Finance]
1/9
11:03 am
bmy
Bristol Myers Squibb (NYSE:BMY) had its "sector perform" rating reaffirmed by analysts at Scotiabank.
Low
Report
Bristol Myers Squibb (NYSE:BMY) had its "sector perform" rating reaffirmed by analysts at Scotiabank.
1/9
09:47 am
bmy
Enhanced Genomics Appoints Dr Katerina Leftheris to Its Board of Directors [Yahoo! Finance]
Low
Report
Enhanced Genomics Appoints Dr Katerina Leftheris to Its Board of Directors [Yahoo! Finance]
1/8
11:43 pm
bmy
Undiscovered Gems in Asia To Explore This January 2026 [Yahoo! Finance]
Low
Report
Undiscovered Gems in Asia To Explore This January 2026 [Yahoo! Finance]
1/7
06:28 pm
bmy
Assessing Bristol Myers Squibb (BMY) Valuation As Shares Gain And Profitability Narrative Evolves [Yahoo! Finance]
Low
Report
Assessing Bristol Myers Squibb (BMY) Valuation As Shares Gain And Profitability Narrative Evolves [Yahoo! Finance]
1/7
05:38 pm
bmy
Is Bristol Myers Squibb (BMY) Pricing Reflect Recent Opdivo And Eliquis Patent Cliff Risks [Yahoo! Finance]
Low
Report
Is Bristol Myers Squibb (BMY) Pricing Reflect Recent Opdivo And Eliquis Patent Cliff Risks [Yahoo! Finance]
1/7
04:37 pm
bmy
3 Drug Stocks to Buy at a Discount [Yahoo! Finance]
Low
Report
3 Drug Stocks to Buy at a Discount [Yahoo! Finance]
1/7
02:16 pm
bmy
RFU Helix 51 Incubator Company Receives Illinois Innovation Voucher Grant Award for Cancer-Drug Development [Yahoo! Finance]
Low
Report
RFU Helix 51 Incubator Company Receives Illinois Innovation Voucher Grant Award for Cancer-Drug Development [Yahoo! Finance]
1/7
08:42 am
bmy
Bristol Myers Squibb (NYSE:BMY) was upgraded by analysts at UBS Group AG from a "neutral" rating to a "buy" rating. They now have a $65.00 price target on the stock.
Medium
Report
Bristol Myers Squibb (NYSE:BMY) was upgraded by analysts at UBS Group AG from a "neutral" rating to a "buy" rating. They now have a $65.00 price target on the stock.
1/7
08:27 am
bmy
Poplar Therapeutics Launches With $50M Series A to Advance a New Class of Anti-IgE Therapy for Multiple Atopic Conditions [Yahoo! Finance]
Medium
Report
Poplar Therapeutics Launches With $50M Series A to Advance a New Class of Anti-IgE Therapy for Multiple Atopic Conditions [Yahoo! Finance]
1/7
07:08 am
bmy
Bristol Myers Squibb (NYSE:BMY) had its "neutral" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
Bristol Myers Squibb (NYSE:BMY) had its "neutral" rating reaffirmed by analysts at Citigroup Inc..